Update and clarification:
May 14, 2016
Highlights
- •
Clarification
on how to select target lesions and what to do with measurable lesions
which are not selected for target disease response assessment.
- •
Clarification on the definition of stable disease.
- •
Clarification
on the role of Fluorodeoxy-glucose (18F) (FDG)-positron emission
tomography (PET)/PET-computed tomography in the context of RECIST 1.1.
The
Response Evaluation Criteria in Solid Tumours (RECIST) were developed
and published in 2000, based on the original World Health Organisation
guidelines first published in 1981. In 2009, revisions were made (RECIST
1.1) incorporating major changes, including a reduction in the number
of lesions to be assessed, a new measurement method to classify lymph
nodes as pathologic or normal, the clarification of the requirement to
confirm a complete response or partial response and new methodologies
for more appropriate measurement of disease progression. The purpose of this paper was to summarise the questions
posed and the clarifications provided as an update to the 2009
publication.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.